Beckman Coulter at outperform by RBC

RBC Capital Markets analyst William R. Quirk gave Beckman Coulter, Inc. an outperform rating, above average risk, following the company's analyst day. The company plans to focus its fledgling molecular platform on pharmacogenomic assay development coupled with proprietary assays longer term, according to the analyst. Beckman management highlighted two assays currently under development, Inhibin A for maternal risk assessment and PaPPA (Pregnancy associated Plasma Protein A) for maternal and cardiac risk assessment. Shares of the Fullerton, Calif.-based biomedical company were up 55 cents, or 1.00%, at $55.67 on volume of 352,200 shares versus the three-month running average of 470,420 shares. NYSE: CVD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.